AmerZeidanMDMBBS, MHS

Oncology • New Haven, CT

Hematologic Oncology

Assistant Professor of medicine, Yale university

Join to view full profile

Dr. Zeidan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Zeidan's full profile

Already have an account?

Office
20 York St
New Haven, CT 06510
Phone+1 203-688-4242

Fax+1 203-688-5013
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Jordan Faculty of MedicineClass of 2001
Rochester General HospitalResidency, Internal Medicine

Certifications & Licensure

CT State Medical License 2014 - 2024
MD State Medical License 2010 - 2015
NY State Medical License 2007 - 2014
American Board of Internal Medicine Hematology

Clinical Trials

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents Start of enrollment: 2017 Jun 23
Active, not recruiting
Phase 1
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Start of enrollment: 2019 Jun 26
Recruiting
Phase 2
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
Terminated
Phase 2
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia Start of enrollment: 2021 Feb 16
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
Maximillian Stahl, Tariq Kewan, Jan Philipp Bewersdorf, Amer M Zeidan> ;Current Hematologic Malignancy Reports. 2024 Apr 18
CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) ...
Yazan Madanat, Michael R Savona, Mikkael A Sekeres, Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Maria Diez-Campelo, David Valcárcel, Tymara Berry, Souria Doughert...> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidis...
Ryan Haumschild, Julie Kennerly-Shah, Lisa Barbarotta, Amer M Zeidan> ;Journal of Oncology Pharmacy Practice. 2024 Mar 21
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.
Pau Montesinos, Stéphane de Botton, Yue Zhu, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Amir T Fathi, Eytan M Stein, Amer M Zeidan, Thomas Prebet, Courtney D DiNardo> ;Blood Advances. 2024 Mar 20
1 citations
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shai Shimony, Jan Philipp Bewersdorf, Rory M Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Ev...> ;Leukemia. 2024 Apr 1
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: resul...
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Adam S ...> ;Blood Cancer Journal. 2024 Feb 20
PD-1H/VISTA mediates immune evasion in acute myeloid leukemia.
Kim, T., Han, X., Hu, Q., Vandsemb, E., Fielder, C., Hong, J., Kim, K., Mason, E., Plowman, R., Wang, J., Wang, Q., Zhang, J., Badri, T., Sanmamed, M., Zheng, L., Zhan...> ;The Journal of Clinical Investigation. 2024 Feb 1
Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country.
Abdalla Awidi, Marah Alzu'bi, Nada Odeh, Jawad Alrawabdeh, Muntaser Al Zyoud, Yazan Hamadneh, Hisham Bawa'neh, Ahmad Magableh, Alaa Alshorman, Feras Al-Fararjeh, Tariq...> ;JCO Global Oncology. 2024 Feb 1
3 citations
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised...
Garcia-Manero, G., McCloskey, J., Griffiths, E., Yee, K., Zeidan, A., Al-Kali, A., Deeg, H., Patel, P., Sabloff, M., Keating, M., Zhu, N., Gabrail, N., Fazal, S., Maly...> ;The Lancet. Haematology. 2024 Jan 1
2 citations
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placeb...
Zeidan, A., Ando, K., Rauzy, O., Turgut, M., Wang, M., Cairoli, R., Hou, H., Kwong, Y., Arnan, M., Meers, S., Pullarkat, V., Santini, V., Malek, K., Kiertsman, F., Nio...> ;The Lancet. Haematology. 2024 Jan 1
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or ...
Jan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E Roe, Jonathan M Irish, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan ...> ;Annals of Hematology. 2024 Jan 1
4 citations
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, ra...
Platzbecker, U., Santini, V., Fenaux, P., Sekeres, M., Savona, M., Madanat, Y., Díez-Campelo, M., Valcárcel, D., Illmer, T., Jonášová, A., Bělohlávková, P., Sherman, L...> ;Lancet. 2024 Jan 20
When to use which molecular prognostic scoring system in the management of patients with MDS?
Gurnari, C., Kewan, T., Bewersdorf, J., Xie, Z., Zeidan, A., Stahl, M.> ;Best Practice & Research. Clinical Haematology. 2023 Dec 1
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists.
Yazan F Madanat, Amer M Zeidan> ;Clinics in Laboratory Medicine. 2023 Dec 1
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
Abid, M. B., Hemant S Murthy, Mei-Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly, Ankit Kansagra, Fotios V Michelis, Taiga Nishihori, Mrinal Pat...> ;Blood Advances. 2023 Nov 28
Traditional Medicare or Medicare Advantage? The Leukemia and Cancer Perspective.
Rajkumar, V., Kantarjian, H., Zeidan, A., Fathi, A., Stein, E., Tefferi, A.> ;Mayo Clinic Proceedings. 2024 Jan 1
4 citations
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Cons...
Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L Xu, Omar Abdel-Wahab, Justin Taylor, David P Steensma, Daniel ...> ;Blood Reviews. 2023 Nov 1
Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).
Amer M Zeidan, Elizabeth S Mearns, Carmen D Ng, Anuj Shah, Neil Lamarre, Archibong Yellow-Duke, Neda Alrawashdh, Baiyu Yang, Wei-Han Cheng, Cat N Bui, Anders Svensson> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Mar 1
2 citations
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelody...
Uwe Platzbecker, Valeria Santini, Rami S Komrokji, Amer M Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Dimana Miteva, Karen Keeperman, Natalia Holot, Jose Alberto ...> ;Leukemia. 2023 Nov 1
Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms.
Talha Badar, Yazan F Madanat, Amer M Zeidan> ;Future Oncology. 2023 Sep 1
Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refra...
Peter J P Croucher, Maya Ridinger, Pamela S Becker, Tara L Lin, Sandra L Silberman, Eunice S Wang, Amer M Zeidan> ;Annals of Hematology. 2023 Nov 1
2 citations
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia.
Nikolai A Podoltsev, Rong Wang, Rory M Shallis, Jessica M Stempel, Mengyang Di, Natalia Neparidze, Amer M Zeidan, Scott F Huntington, Smith Giri, Sarah C Hull, Steven ...> ;Cancer Medicine. 2023 Sep 1
3 citations
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Shallis, R., Daver, N., Altman, J., Komrokji, R., Pollyea, D., Badar, T., Bewersdorf, J., Bhatt, V., de Botton, S., de la Fuente Burguera, A., Carraway, H., Desai, P.,...> ;The Lancet. Haematology. 2023 Sep 1
1 citations
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution.
Enrico Santinelli, Maria Rosaria Pascale, Zhuoer Xie, Talha Badar, Maximilian F Stahl, Jan P Bewersdorf, Carmelo Gurnari, Amer M Zeidan> ;Blood Reviews. 2023 Nov 1
Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.
Sangeetha Venugopal, Rory M Shallis, Amer M Zeidan> ;Expert Review of Anticancer Therapy. 2023 Jul 20
Join now to see all

Lectures

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Is AML Harder to Treat After Relapse?March 6th, 2020
Trovagene (TROV) Stock: Providing New Cancer Treatment Options with OnvansertibDecember 11th, 2018
$Breaking News: Trovagene Reports New Data from Phase 1b/2 Study of Onvansertib Demonstrates Response to Treatment in Relapsed/Refractory AML$
Breaking News: Trovagene Reports New Data from Phase 1b/2 Study of Onvansertib Demonstrates Response to Treatment in Relapsed/Refractory AMLDecember 3rd, 2018
Join now to see all